Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This phase II trial tests a new drug called SKB500 in combination with standard chemotherapy and immunotherapy for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery. The study will evaluate how well the combination shrinks tumors and how sa…

This phase II trial is testing whether a combination of two drugs, SKB264 and SKB118, can safely shrink tumors in people with advanced non-small cell lung cancer that has spread. The study includes a dose-finding phase and an expansion phase to better understand the treatment's e…

This study tests a new drug called SKB571 in 30 adults with head and neck cancer that has returned or spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug and be monitored for response and…

This phase 2 trial tests a new drug called SKB571 combined with other cancer medicines in 150 people with non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. Participants will receive the drugs by injection or mouth, and re…

This study tests a new drug combination (SKB315 plus an immunotherapy) in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 80 participants in China will receive the treatment to see if it shrinks tumors. The goal is to cont…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This study tests a new drug called SKB571 in 120 adults with gastrointestinal tumors. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug and be monitored for side effects and cancer progression. The study is not yet recruiting.

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This phase 2 trial tests a drug called sacituzumab tirumotecan (Sac-TMT) in 30 people with advanced thymic carcinoma that has worsened after platinum-based chemotherapy. Participants receive the drug every two weeks, and doctors will check how well it shrinks tumors and monitor s…